Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)

Cabio Biotech (Wuhan) Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	581.23	542.29	435.39	402.08	350.76	323.26
Other Revenue	13.31	13.31	8.41	31.35	0.35	0.21
Revenue	594.54	555.59	443.8	433.42	351.11	323.46
Revenue Growth (YoY)	25.68%	25.19%	2.40%	23.44%	8.55%	3.82%
Cost of Revenue	337.1	326.81	264.51	257.14	172.33	153.14
Gross Profit	257.44	228.78	179.29	176.29	178.78	170.32
Selling, General & Admin	70.7	72.35	56.34	64.32	42.18	35.75
Research & Development	46.36	47.57	38.23	31.84	30.54	20.18
Other Operating Expenses	6.84	5.36	6.38	4.56	5.01	4.6
Operating Expenses	131.9	125.82	103.21	111.93	77.08	60.56
Operating Income	125.54	102.97	76.08	64.35	101.7	109.76
Interest Expense	-0.45	-0.4	-0.6	-0.37	-0.35	-
Interest & Investment Income	7.78	3.52	7.41	7.12	16.83	20.84
Currency Exchange Gain (Loss)	2.78	2.78	1.08	11.28	-2.6	-6.37
Other Non Operating Income (Expenses)	-2.14	-2.31	26.37	23.94	34.41	31.99
EBT Excluding Unusual Items	133.52	106.56	110.34	106.33	149.99	156.21
Gain (Loss) on Sale of Investments	-3.68	0.27	-2.64	-37.8	0.99	3.02
Gain (Loss) on Sale of Assets	-0	-0	0.05	0	-2.4	-1.31
Asset Writedown	-5.54	-5.21	-4.13	-0.69	-	-
Other Unusual Items	39.2	38.21	-3.62	10.29	3.48	-0.2
Pretax Income	163.5	139.82	100	78.14	152.06	157.73
Income Tax Expense	22.65	19.69	13.63	16.56	20.77	22.8
Earnings From Continuing Operations	140.85	120.13	86.37	61.58	131.29	134.94
Minority Interest in Earnings	4.05	4.08	5.01	2.79	-2.72	-4.35
Net Income	144.9	124.21	91.37	64.37	128.58	130.59
Net Income to Common	144.9	124.21	91.37	64.37	128.58	130.59
Net Income Growth	42.92%	35.94%	41.95%	-49.94%	-1.54%	10.50%
Shares Outstanding (Basic)	166	168	169	169	168	168
Shares Outstanding (Diluted)	166	168	169	169	168	168
Shares Change (YoY)	-3.92%	-0.80%	-0.11%	0.69%	0.31%	32.80%
EPS (Basic)	0.87	0.74	0.54	0.38	0.76	0.78
EPS (Diluted)	0.87	0.74	0.54	0.38	0.76	0.78
EPS Growth	48.76%	37.04%	42.10%	-50.28%	-1.84%	-16.79%
Free Cash Flow	-34.45	-38.55	-228.79	-73.07	-70.14	112.78
Free Cash Flow Per Share	-0.21	-0.23	-1.35	-0.43	-0.42	0.67
Dividend Per Share	0.200	0.200	0.200	0.214	0.236	0.236
Dividend Growth	-	-	-6.67%	-9.08%	-	-34.00%
Gross Margin	43.30%	41.18%	40.40%	40.67%	50.92%	52.66%
Operating Margin	21.12%	18.53%	17.14%	14.85%	28.97%	33.93%
Profit Margin	24.37%	22.36%	20.59%	14.85%	36.62%	40.37%
Free Cash Flow Margin	-5.79%	-6.94%	-51.55%	-16.86%	-19.98%	34.87%
EBITDA	181.59	157.22	123.14	90.4	125.02	135.78
EBITDA Margin	30.54%	28.30%	27.74%	20.86%	35.61%	41.98%
D&A For EBITDA	56.05	54.25	47.06	26.04	23.32	26.01
EBIT	125.54	102.97	76.08	64.35	101.7	109.76
EBIT Margin	21.12%	18.53%	17.14%	14.85%	28.97%	33.93%
Effective Tax Rate	13.85%	14.08%	13.63%	21.19%	13.66%	14.45%
Revenue as Reported	594.54	555.59	443.8	433.42	351.11	323.46
Advertising Expenses	-	6.61	5.28	2.27	1.11	0.88

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.